CRISPR Therapeutics AG
CRSP
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.16B
Close$
$-0.49
100.9% downside
Current Fair Value
100.9% downsideOvervalued by 100.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.16 Billion |
|---|---|
| Enterprise Value | $5.67 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.47 |
| Beta | 1.7 |
| Outstanding Shares | 96,514,102 |
Return
| Return on Equity | -25.83% |
|---|---|
| Return on Assets | -17.02% |
| Return on Invested Capital | -20.08% |
Valuation & Multiples
| P/E Ratio | -11.24 |
|---|---|
| PEG | 19.97 |
| Price to Sales | - |
| Price to Book Ratio | 3.0 |
| Enterprise Value to Revenue | 423.35 |
| Enterprise Value to EBIT | -11.21 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.46 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-1.19
Average shareholder expectationRevenue Estimate
$7.45 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-1.06
Average shareholder expectationRevenue Estimate
$14.06 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0679▲ 23.01% |
|---|---|
| Total Calls | 135,400▼ 93.52% |
| Total Puts | 144,600▼ 91.74% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.22%▼ 61.10% |
|---|---|
| Total Invested | $1.01B▼ 72.59% |
| Investors Holding | 261▼ 263.00% |
ESG Score
No data
About CRISPR Therapeutics AG
CEO: Samarth Kulkarni